AR099569A1 - Derivados de insulina y los usos médicos de estos - Google Patents
Derivados de insulina y los usos médicos de estosInfo
- Publication number
- AR099569A1 AR099569A1 ARP150100559A ARP150100559A AR099569A1 AR 099569 A1 AR099569 A1 AR 099569A1 AR P150100559 A ARP150100559 A AR P150100559A AR P150100559 A ARP150100559 A AR P150100559A AR 099569 A1 AR099569 A1 AR 099569A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- insulin derivatives
- medical uses
- diabetes
- refers
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157215 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099569A1 true AR099569A1 (es) | 2016-08-03 |
Family
ID=50184804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100559A AR099569A1 (es) | 2014-02-28 | 2015-02-25 | Derivados de insulina y los usos médicos de estos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10040839B2 (enExample) |
| EP (1) | EP3110840B1 (enExample) |
| JP (1) | JP6580583B2 (enExample) |
| KR (1) | KR20160125988A (enExample) |
| CN (1) | CN106459171B (enExample) |
| AR (1) | AR099569A1 (enExample) |
| AU (1) | AU2015222135B2 (enExample) |
| BR (1) | BR112016017193A2 (enExample) |
| CA (1) | CA2941103A1 (enExample) |
| DK (1) | DK3110840T3 (enExample) |
| ES (1) | ES2831848T3 (enExample) |
| HR (1) | HRP20201732T1 (enExample) |
| HU (1) | HUE051355T2 (enExample) |
| IL (1) | IL246757B (enExample) |
| MX (1) | MX368387B (enExample) |
| PL (1) | PL3110840T3 (enExample) |
| PT (1) | PT3110840T (enExample) |
| RS (1) | RS61137B1 (enExample) |
| RU (1) | RU2684456C2 (enExample) |
| SA (1) | SA516371705B1 (enExample) |
| SI (1) | SI3110840T1 (enExample) |
| TW (1) | TWI686403B (enExample) |
| WO (1) | WO2015128403A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015131902A1 (en) * | 2014-03-07 | 2015-09-11 | Jørgensen Klavs Holger | Novel fast acting insulin preparations |
| CN108026157B (zh) | 2015-08-25 | 2022-11-25 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| WO2018094388A1 (en) * | 2016-11-21 | 2018-05-24 | Case Western Reserve University | Rapid-acting insulin analogues of enhanced stability |
| KR101909052B1 (ko) * | 2017-02-09 | 2018-10-17 | 강원대학교산학협력단 | 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물 |
| EP3606560A2 (en) * | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| AU2018317810A1 (en) * | 2017-08-17 | 2020-03-19 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| MA50414A (fr) * | 2017-10-19 | 2020-08-26 | Mona E Buice | Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes |
| TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| SG11202106168VA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin analogs having reduced insulin receptor binding affinity |
| CA3127312A1 (en) | 2019-02-13 | 2020-08-20 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin derivative having cysteine residue |
| JP7479302B2 (ja) * | 2019-02-13 | 2024-05-08 | 住友ファーマ株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| MX2022002433A (es) * | 2019-08-27 | 2022-05-19 | Zp Spv 3 K/S | Análogos de compstatina y sus usos médicos. |
| MA58093B1 (fr) | 2019-12-11 | 2024-09-30 | Novo Nordisk A/S | Nouveaux analogues d'insuline et leurs utilisations |
| WO2021136293A1 (zh) * | 2019-12-30 | 2021-07-08 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| JP2024521757A (ja) * | 2021-05-24 | 2024-06-04 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 新規なアシル化インスリンアナログ |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3864325A (en) | 1971-11-18 | 1975-02-04 | Nat Res Dev | (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| JPH04502465A (ja) * | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| EP0506792B1 (en) * | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| BR9407508A (pt) | 1993-09-17 | 1997-01-07 | Novo Nordisk As | Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6703017B1 (en) * | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US5898067A (en) | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| ATE321783T1 (de) | 1997-03-20 | 2006-04-15 | Novo Nordisk As | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| AU757933B2 (en) | 1997-10-24 | 2003-03-13 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| EA200000453A1 (ru) | 1997-10-24 | 2000-10-30 | Эли Лилли Энд Компани | Композиции нерастворимого инсулина |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1086130A1 (en) | 1998-06-12 | 2001-03-28 | Kings College London | Insulin analogue |
| EP1196446A1 (en) | 1999-06-29 | 2002-04-17 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| AU2001264789A1 (en) | 2000-06-08 | 2001-12-17 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| WO2003048195A2 (en) | 2001-12-02 | 2003-06-12 | Novo Nordisk A/S | Glucose dependant release of insulin from glucose sensing insulin derivatives |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| WO2003075950A1 (en) | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| WO2004096854A2 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1644411A2 (en) | 2003-07-11 | 2006-04-12 | Novo Nordisk A/S | Stabilised insulin compositions |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| AU2004264958B2 (en) | 2003-08-13 | 2010-04-15 | Biocon, Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| JP2007532096A (ja) | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| RU2527893C2 (ru) | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| ES2438145T3 (es) | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| ES2490243T3 (es) | 2005-02-02 | 2014-09-03 | Novo Nordisk A/S | Derivados de insulina |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| EP2024390B1 (en) | 2006-05-09 | 2015-08-19 | Novo Nordisk A/S | Insulin derivative |
| AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| EP2076242B8 (en) | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| JP5550338B2 (ja) | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| US9018161B2 (en) * | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
| WO2008145721A2 (en) | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| WO2009015456A1 (en) | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
| AU2008288413B2 (en) | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| JP5715418B2 (ja) | 2007-11-08 | 2015-05-07 | ノボ・ノルデイスク・エー／エス | インスリン誘導体 |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| ES2618073T3 (es) * | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| WO2010029159A1 (en) | 2008-09-12 | 2010-03-18 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| EP2352513B1 (en) | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| CA2769540C (en) * | 2009-07-31 | 2017-08-15 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
| WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| JP5973427B2 (ja) | 2010-06-23 | 2016-08-23 | ノヴォ ノルディスク アー／エス | 追加のジスルフィド結合を含有するインスリン類似体 |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| US9655974B2 (en) | 2010-07-20 | 2017-05-23 | Novo Nordisk A/S | N-terminal modified FGF21 compounds |
| US9260503B2 (en) | 2011-06-15 | 2016-02-16 | Novo Nordisk A/S | Multi-substituted insulins |
| AU2012328407A1 (en) | 2011-10-27 | 2014-05-22 | Case Western Reserve University | Ultra-concentrated rapid-acting insulin analogue formulations |
-
2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
- 2015-02-26 HR HRP20201732TT patent/HRP20201732T1/hr unknown
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/en active Active
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en not_active Ceased
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Withdrawn
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
-
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016010899A (es) | 2016-11-18 |
| CA2941103A1 (en) | 2015-09-03 |
| HRP20201732T1 (hr) | 2020-12-25 |
| WO2015128403A2 (en) | 2015-09-03 |
| US20170008945A1 (en) | 2017-01-12 |
| RU2016135543A3 (enExample) | 2018-08-30 |
| TWI686403B (zh) | 2020-03-01 |
| AU2015222135A1 (en) | 2016-07-28 |
| TW201620930A (zh) | 2016-06-16 |
| KR20160125988A (ko) | 2016-11-01 |
| SI3110840T1 (sl) | 2020-12-31 |
| IL246757A0 (en) | 2016-08-31 |
| WO2015128403A3 (en) | 2015-12-10 |
| JP6580583B2 (ja) | 2019-09-25 |
| US10040839B2 (en) | 2018-08-07 |
| AU2015222135B2 (en) | 2018-12-20 |
| RU2016135543A (ru) | 2018-03-30 |
| BR112016017193A2 (pt) | 2017-10-03 |
| EP3110840B1 (en) | 2020-10-21 |
| CN106459171B (zh) | 2020-12-15 |
| HUE051355T2 (hu) | 2021-03-01 |
| JP2017508741A (ja) | 2017-03-30 |
| RS61137B1 (sr) | 2020-12-31 |
| EP3110840A2 (en) | 2017-01-04 |
| RU2684456C2 (ru) | 2019-04-09 |
| SA516371705B1 (ar) | 2019-10-08 |
| ES2831848T3 (es) | 2021-06-09 |
| PT3110840T (pt) | 2020-11-26 |
| DK3110840T3 (da) | 2020-11-02 |
| MX368387B (es) | 2019-10-01 |
| IL246757B (en) | 2020-04-30 |
| CN106459171A (zh) | 2017-02-22 |
| PL3110840T3 (pl) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| ECSP20040257A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| DOP2016000271A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
| DOP2015000241A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
| NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| JOP20200097A1 (ar) | معدل مستقبل أندروجين واستخداماته | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| CO2019006017A2 (es) | Composiciones farmacéuticas que contienen insulina | |
| UY35586A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP13013068A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| SV2016005330A (es) | Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| CL2020000310A1 (es) | Análogos de insulina acilados novedosos y usos de estos. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2017001539A1 (es) | Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos | |
| EA201692278A1 (ru) | Комбинации формотерола и будесонида для лечения хобл |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |